Literature DB >> 29769727

Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host.

Marlies Meisel1,2, Reinhard Hinterleitner1,2, Alain Pacis3,4, Li Chen1,2, Zachary M Earley1,2, Toufic Mayassi1,2, Joseph F Pierre1,5, Jordan D Ernest1,2, Heather J Galipeau6, Nikolaus Thuille7, Romain Bouziat1,2, Manuel Buscarlet8, Daina L Ringus1, Yitang Wang9, Ye Li9, Vu Dinh1,2, Sangman M Kim1,2, Benjamin D McDonald1,9, Matthew A Zurenski1,2, Mark W Musch1, Glaucia C Furtado10, Sergio A Lira10, Gottfried Baier7, Eugene B Chang1, A Murat Eren1,11, Christopher R Weber9, Lambert Busque8,12, Lucy A Godley1,13, Elena F Verdú6, Luis B Barreiro3,14, Bana Jabri15,16,17.   

Abstract

Somatic mutations in tet methylcytosine dioxygenase 2 (TET2), which encodes an epigenetic modifier enzyme, drive the development of haematopoietic malignancies1-7. In both humans and mice, TET2 deficiency leads to increased self-renewal of haematopoietic stem cells with a net developmental bias towards the myeloid lineage1,4,8,9. However, pre-leukaemic myeloproliferation (PMP) occurs in only a fraction of Tet2-/- mice8,9 and humans with TET2 mutations1,3,5-7, suggesting that extrinsic non-cell-autonomous factors are required for disease onset. Here we show that bacterial translocation and increased interleukin-6 production, resulting from dysfunction of the small-intestinal barrier, are critical for the development of PMP in mice that lack Tet2 expression in haematopoietic cells. Furthermore, in symptom-free Tet2-/- mice, PMP can be induced by disrupting intestinal barrier integrity, or in response to systemic bacterial stimuli such as the toll-like receptor 2 agonist. PMP was reversed by antibiotic treatment and failed to develop in germ-free Tet2-/- mice, which illustrates the importance of microbial signals in the development of this condition. Our findings demonstrate the requirement for microbial-dependent inflammation in the development of PMP and provide a mechanistic basis for the variation in PMP penetrance observed in Tet2-/- mice. This study will prompt new lines of investigation that may profoundly affect the prevention and management of haematopoietic malignancies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29769727      PMCID: PMC6238954          DOI: 10.1038/s41586-018-0125-z

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  40 in total

Review 1.  Clonal hematopoiesis.

Authors:  Max Jan; Benjamin L Ebert; Siddhartha Jaiswal
Journal:  Semin Hematol       Date:  2016-10-20       Impact factor: 3.851

2.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Authors:  Cyril Quivoron; Lucile Couronné; Véronique Della Valle; Cécile K Lopez; Isabelle Plo; Orianne Wagner-Ballon; Marcio Do Cruzeiro; Francois Delhommeau; Bertrand Arnulf; Marc-Henri Stern; Lucy Godley; Paule Opolon; Hervé Tilly; Eric Solary; Yannis Duffourd; Philippe Dessen; Hélène Merle-Beral; Florence Nguyen-Khac; Michaëla Fontenay; William Vainchenker; Christian Bastard; Thomas Mercher; Olivier A Bernard
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

3.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

Authors:  Kelly Moran-Crusio; Linsey Reavie; Alan Shih; Omar Abdel-Wahab; Delphine Ndiaye-Lobry; Camille Lobry; Maria E Figueroa; Aparna Vasanthakumar; Jay Patel; Xinyang Zhao; Fabiana Perna; Suveg Pandey; Jozef Madzo; Chunxiao Song; Qing Dai; Chuan He; Sherif Ibrahim; Miloslav Beran; Jiri Zavadil; Stephen D Nimer; Ari Melnick; Lucy A Godley; Iannis Aifantis; Ross L Levine
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

4.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

5.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

Review 6.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Authors:  Robert L Bowman; Lambert Busque; Ross L Levine
Journal:  Cell Stem Cell       Date:  2018-02-01       Impact factor: 24.633

7.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

8.  TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.

Authors:  Olivier Kosmider; Véronique Gelsi-Boyer; Marion Ciudad; Cindy Racoeur; Valérie Jooste; Norbert Vey; Bruno Quesnel; Pierre Fenaux; Jean-Noël Bastie; Odile Beyne-Rauzy; Aspasia Stamatoulas; François Dreyfus; Norbert Ifrah; Stéphane de Botton; William Vainchenker; Oliver A Bernard; Daniel Birnbaum; Michaëla Fontenay; Eric Solary
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

Review 9.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

Authors:  Omar Abdel-Wahab; Ross L Levine
Journal:  Blood       Date:  2013-05-02       Impact factor: 22.113

10.  Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.

Authors:  Lambert Busque; Jay P Patel; Maria E Figueroa; Aparna Vasanthakumar; Sylvie Provost; Zineb Hamilou; Luigina Mollica; Juan Li; Agnes Viale; Adriana Heguy; Maryam Hassimi; Nicholas Socci; Parva K Bhatt; Mithat Gonen; Christopher E Mason; Ari Melnick; Lucy A Godley; Cameron W Brennan; Omar Abdel-Wahab; Ross L Levine
Journal:  Nat Genet       Date:  2012-09-23       Impact factor: 38.330

View more
  112 in total

Review 1.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.

Authors:  Zhigang Cai; Jonathan J Kotzin; Baskar Ramdas; Sisi Chen; Sai Nelanuthala; Lakshmi Reddy Palam; Ruchi Pandey; Raghuveer Singh Mali; Yan Liu; Mark R Kelley; George Sandusky; Morvarid Mohseni; Adam Williams; Jorge Henao-Mejia; Reuben Kapur
Journal:  Cell Stem Cell       Date:  2018-12-06       Impact factor: 24.633

3.  High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential.

Authors:  Lambert Busque; Maxine Sun; Manuel Buscarlet; Sami Ayachi; Yassamin Feroz Zada; Sylvie Provost; Vincent Bourgoin; Luigina Mollica; Marlies Meisel; Reinhard Hinterleitner; Bana Jabri; Marie-Pierre Dubé; Jean-Claude Tardif
Journal:  Blood Adv       Date:  2020-06-09

Review 4.  Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies.

Authors:  Chan-Wang J Lio; Hiroshi Yuita; Anjana Rao
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

5.  Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies.

Authors:  Hongxiang Zeng; Hailan He; Lei Guo; Jia Li; Minjung Lee; Wei Han; Anna G Guzman; Shengbing Zang; Yubin Zhou; Xiaotian Zhang; Margaret A Goodell; Katherine Y King; Deqiang Sun; Yun Huang
Journal:  Cancer Lett       Date:  2019-09-26       Impact factor: 8.679

6.  The role of type 1 interferons in coagulation induced by gram-negative bacteria.

Authors:  Xinyu Yang; Xiaoye Cheng; Yiting Tang; Xianhui Qiu; Zhongtai Wang; Guang Fu; Jianfeng Wu; Haixia Kang; Jing Wang; Haichao Wang; Fangping Chen; Xianzhong Xiao; Timothy R Billiar; Ben Lu
Journal:  Blood       Date:  2020-04-02       Impact factor: 22.113

7.  Clonal hematopoiesis: mechanisms driving dominance of stem cell clones.

Authors:  Grant A Challen; Margaret A Goodell
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

Review 8.  Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis.

Authors:  Jennifer M SanMiguel; Kira Young; Jennifer J Trowbridge
Journal:  Exp Hematol       Date:  2020-09-28       Impact factor: 3.084

9.  TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.

Authors:  Xiaojing Yue; Anjana Rao
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

Review 10.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.